The big news of last week was the Federal Reserve cutting interest rates for the first time in 2025. But it didn’t move the needle much for stocks — in fact, the Nasdaq Composite sank, and the S&P 500 was flat. That’s because the 25 basis-point cut was likely already baked in, as just about everyone knew it was coming…
Which exchange-traded funds have consistently beaten the stock market’s benchmark index and are still doing it in 2025? Not only have these stalwart ETFs outpaced the S&P 500 over the past decade, they’re also some of the best performers of the year so far. While there’s no guarantee that these funds will continue to win, especially given tech’s outsized influence…
Last week, I explained why I believe uranium will outperform gold over the remainder of this decade. As I noted then, “there is an energy crisis brewing due to rapidly increasing demand for data centers to support artificial intelligence (AI).” Without a doubt, demand for uranium will increase as this country expands its nuclear power capabilities. But there is another…
Semiconductor giant Intel (INTC) entered this year in a state of disarray. It had no permanent CEO until March, when industry veteran Lip-Bu Tan took over after former CEO Pat Gelsinger was forced out. Intel’s foundry business, a capital-intensive endeavor meant to open up Intel’s manufacturing technology and facilities to third-party customers, wasn’t winning meaningful customers. Tan made it clear that without significant…
Artificial intelligence has enhanced many industries, including health care, and health professionals now have access to a wider range of AI tools and additional data points on each patient. This information can help pinpoint conditions, help prevent diseases from spreading and aid in patient monitoring, as well as help manage prescriptions and tackle administrative tasks. AI will continue to enhance…
It’s easy to think of the major U.S. stock market indexes as permanent and unchanging over the decades. The financial equivalent of Mount Rushmore. But unlike that famous monument chiseled into the South Dakota hills, the corporate icons enshrined in the Dow Jones aren’t exactly set in stone. In fact, there have been 59 changes made over the years by…
Some prominent biotech companies tend to capture the majority of investors’ and analysts’ attention compared to their industry peers. aTyr Pharma (ATYR), a small-cap, clinical-stage biotech, doesn’t belong to that group. However, the drugmaker has performed well this year; its shares are up 40% year to date. What’s more, aTyr Pharma could have even more upside in the (very) near future. Is…
In December 2022, researchers at the Lawrence Livermore National Laboratory’s National Ignition Facility in California conducted a controlled nuclear fusion experiment that, for the first time, produced more energy than was delivered by the lasers used to initiate it. That historic breakthrough has triggered a nuclear fusion technology arms race, and it’s understandable why investors are excited about the possibility…
Now that the Labor Day weekend is behind us, it’s time to focus on the one thing that unites most Americans: football season! Just as the favorites don’t always win at football, the stock market isn’t always the best place to invest your money. That doesn’t often happen, but one of those times may be coming this fall depending on…
The large cap indexes all set new records in August, but it wasn’t the usual suspects that led the way. AI juggernauts Nvidia (NASDAQ:NVDA) and Palantir (NASDAQ:PLTR) barely tread water last month, with Nvidia down slightly, about 1%, and Palantir breaking even. There is an underlying concern among many investors about an AI bubble, similar to the dotcom bubble of the early 2000s. The…